Scott Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Scott Johnson has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Shay Golan
The University of Chicago, Department of Surgery, Section of Urology, Chicago, IL
5 shared publications- Gary D. Steinberg
Department of Urology, NYU Langone Health, New York, NY, USA
4 shared publications Norm D. Smith
The University of Chicago, Department of Surgery, Section of Urology, Chicago, IL
4 shared publicationsArieh Shalhav
Chicago, IL
3 shared publicationsGary Steinberg
Chicago, IL
3 shared publicationsPeter Langenstroer
Medical College of Wisconsin, Milwaukee, WI, USA
3 shared publications
Latest Publications
- Open Access
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadi2742
Stat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling
Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops relatively fast as a result of refueled AR activity. A major gap in the field is the lack of understanding of targetable mechanisms that induce persistent AR expression in castrate-resistant PC (CRPC). This study uncovers an unexpected function of active Stat5 signaling, a known promoter of PC growth and clinical progression, as a potent inducer of AR gene transcription. Stat5 suppression inhibited AR gene transcription in preclinical PC models and reduced the levels of wild-type, mutated, and truncated AR proteins. Pharmacological Stat5 inhibition by a specific small-molecule Stat5 inhibitor down-regulated Stat5-inducible genes as well as AR and AR-regulated genes and suppressed PC growth. This work introduces the concept of Stat5 as an inducer of AR gene transcription in PC. Pharmacological Stat5 inhibitors may represent a new strategy for suppressing AR and CRPC growth.
- 1 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (9) , eadi2742
Open AccessStat5 induces androgen receptor ( AR ) gene transcription in prostate cancer and offers a druggable pathway to target AR signaling
Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops relatively fast as a result of refueled AR activity. A major gap in the field is the lack of understanding of targetable mechanisms that induce persistent AR expression in castrate-resistant PC (CRPC). This study uncovers an unexpected function of active Stat5 signaling, a known promoter of PC growth and clinical progression, as a potent inducer of AR gene transcription. Stat5 suppression inhibited AR gene transcription in preclinical PC models and reduced the levels of wild-type, mutated, and truncated AR proteins. Pharmacological Stat5 inhibition by a specific small-molecule Stat5 inhibitor down-regulated Stat5-inducible genes as well as AR and AR-regulated genes and suppressed PC growth. This work introduces the concept of Stat5 as an inducer of AR gene transcription in PC. Pharmacological Stat5 inhibitors may represent a new strategy for suppressing AR and CRPC growth.
- Open Access
- 5 December 2023
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2023 (12) , rjad674
Benign mature teratoma of the cecum: a case report
A teratoma is a typically benign tumor derived from more than one embryonic cell line, and it is characterized by presence of tissue foreign to the tumor location site. With the unlikely primary location in the gastrointestinal tract and no history of malignancy, we present a rare case of a primary mature cystic teratoma of the cecum. The patient is a 66-year-old male with imaging demonstrating an extraluminal, seemingly fat-containing mass abutting the cecum. The patient underwent resection, and final pathology revealed a mature cystic teratoma. Primary mature teratoma of the cecum is exceptionally rare; thus, diagnosis can be challenging. As he had no primary testicular or retroperitoneal mass, this cystic lesion likely represents a developmental abnormality and not a true neoplasm. The radiographic features, presentation, differential diagnoses, and treatment recommendations are discussed.
- 5 December 2023
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2023 (12) , rjad674
Open AccessBenign mature teratoma of the cecum: a case report
A teratoma is a typically benign tumor derived from more than one embryonic cell line, and it is characterized by presence of tissue foreign to the tumor location site. With the unlikely primary location in the gastrointestinal tract and no history of malignancy, we present a rare case of a primary mature cystic teratoma of the cecum. The patient is a 66-year-old male with imaging demonstrating an extraluminal, seemingly fat-containing mass abutting the cecum. The patient underwent resection, and final pathology revealed a mature cystic teratoma. Primary mature teratoma of the cecum is exceptionally rare; thus, diagnosis can be challenging. As he had no primary testicular or retroperitoneal mass, this cystic lesion likely represents a developmental abnormality and not a true neoplasm. The radiographic features, presentation, differential diagnoses, and treatment recommendations are discussed.
- 29 August 2023
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Taking Charge of Men’s Health: Need for More Comprehensive Care Beyond the Prostate Cancer Diagnosis
Introduction: In this study, we aim to characterize diagnosed and undiagnosed comorbid conditions as well as the sufficiency of their management in order to demonstrate the opportunity available to improve the overall health in men presenting with a new prostate cancer diagnosis. Methods: A retrospective chart review was performed on patients presenting with a new prostate cancer diagnosis from January 2020 to March 2022 to determine undiagnosed conditions and adequacy of the management of comorbidities. Results: Of the included patients, 24.9% had prediabetes, 19.3% diabetes mellitus (DM), 68.5% hypertension (HTN), 70.2% hyperlipidemia (HLD), and 43.1% metabolic syndrome. For DM, HTN, and HLD, 10.5%, 18.8%, and 18.8% of patients were screened but inadequately treated, respectively; 5.5%, 13.8%, and 8.3% were not diagnosed; 2.8%, 0, and 5.5% were not screened. The average 10-year ASCVD risk in patients with metabolic syndrome was 25.6% vs 15.1% in those without ( P < .001), and 21.8% vs 15.1% in patients who were incompletely screened for chronic disease compared with those who were screened per guidelines ( P < .001). Conclusion: The study population has high rates of comorbidities, and undermanaged chronic diseases. This significant unmet health care need represents an opportunity for urologists to champion men’s health in new prostate cancer patients.
- 29 August 2023
- Published by SAGE Publications in American Journal of Lifestyle Medicine
Taking Charge of Men’s Health: Need for More Comprehensive Care Beyond the Prostate Cancer Diagnosis
Introduction: In this study, we aim to characterize diagnosed and undiagnosed comorbid conditions as well as the sufficiency of their management in order to demonstrate the opportunity available to improve the overall health in men presenting with a new prostate cancer diagnosis. Methods: A retrospective chart review was performed on patients presenting with a new prostate cancer diagnosis from January 2020 to March 2022 to determine undiagnosed conditions and adequacy of the management of comorbidities. Results: Of the included patients, 24.9% had prediabetes, 19.3% diabetes mellitus (DM), 68.5% hypertension (HTN), 70.2% hyperlipidemia (HLD), and 43.1% metabolic syndrome. For DM, HTN, and HLD, 10.5%, 18.8%, and 18.8% of patients were screened but inadequately treated, respectively; 5.5%, 13.8%, and 8.3% were not diagnosed; 2.8%, 0, and 5.5% were not screened. The average 10-year ASCVD risk in patients with metabolic syndrome was 25.6% vs 15.1% in those without ( P < .001), and 21.8% vs 15.1% in patients who were incompletely screened for chronic disease compared with those who were screened per guidelines ( P < .001). Conclusion: The study population has high rates of comorbidities, and undermanaged chronic diseases. This significant unmet health care need represents an opportunity for urologists to champion men’s health in new prostate cancer patients.
- 1 November 2021
- Published by Elsevier in European Urology Focus
- Vol. 7 (6) , 1403-1408
Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort
- 1 November 2021
- Published by Elsevier in European Urology Focus
- Vol. 7 (6) , 1403-1408
Primary Robot-assisted Retroperitoneal Lymph Node Dissection for Men with Nonseminomatous Germ Cell Tumor: Experience from a Multi-institutional Cohort
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S607
801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S607
801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)
- Open Access
- 1 November 2018
- Published by Elsevier in Urology Case Reports
- Vol. 21, 116-118
Primary angiosarcoma of the testis with retroperitoneal metastasis
- 1 November 2018
- Published by Elsevier in Urology Case Reports
- Vol. 21, 116-118
Open AccessPrimary angiosarcoma of the testis with retroperitoneal metastasis
- 1 May 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (5) , 237.e19-237.e24
Perioperative and long-term outcomes after radical cystectomy in hemodialysis patients
- 1 May 2018
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 36 (5) , 237.e19-237.e24
Perioperative and long-term outcomes after radical cystectomy in hemodialysis patients
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e820
V08-03 FUNCTIONAL ANATOMY SPARING TECHNIQUE FOR PROSTATECTOMY
Following dissemination of robotic-assisted laparoscopic prostatectomy, enhanced understanding of the periprostatic anatomy has led to improved techniques that spare structures critical to continence and potency. Here we describe our hybrid, accessible approach to radical prostatectomy which preserves functional pelvic anatomy with the goal of improving postoperative continence and potency while simultaneously maintaining oncologic principles.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4) , e820
V08-03 FUNCTIONAL ANATOMY SPARING TECHNIQUE FOR PROSTATECTOMY
Following dissemination of robotic-assisted laparoscopic prostatectomy, enhanced understanding of the periprostatic anatomy has led to improved techniques that spare structures critical to continence and potency. Here we describe our hybrid, accessible approach to radical prostatectomy which preserves functional pelvic anatomy with the goal of improving postoperative continence and potency while simultaneously maintaining oncologic principles.
- 1 March 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (3) , 663-668
Fistulous Complications following Radical Cystectomy for Bladder Cancer: Analysis of a Large Modern Cohort
Fistula formation is a rare and poorly described complication following radical cystectomy with urinary diversion. We sought to identify patients who experienced any type of fistulous complication and we analyzed risk factors for formation as well as management outcomes. We retrospectively reviewed the records of patients who underwent radical cystectomy for bladder cancer at our institution. Patients who experienced any fistula were identified. Risk factors, management strategies and outcomes were analyzed. Patients underwent initial conservative treatment and those in whom this treatment failed underwent surgical repair. Univariable and multivariable analyses were performed to identify predictors of fistula formation as well as the need for surgical repair. Of the 1,041 patients 31 (3.0%) experienced fistula formation. Median time to fistula presentation was 31 days. Enterodiversion was the most common fistula type, noted in 54.8% of patients, followed by enterocutaneous and diversion cutaneous treatment in 29.0% and 12.9%, respectively. On multivariable analyses a history of radiation therapy (OR 3.1, p = 0.03) and an orthotopic neobladder (OR 3.1, p = 0.04) were predictors of fistula formation. Conservative management was successful in 41.9% of cases. There were no predictors of failed conservative management. Of patients who required surgical repair success was achieved in 94.4% at a single operation. Fistulas are rare after radical cystectomy and they are most common between the urinary diversion and the small bowel. A history of radiation therapy and a orthotopic neobladder are risk factors for formation. When required, surgical repair is generally successful at a single operation.
- 1 March 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (3) , 663-668
Fistulous Complications following Radical Cystectomy for Bladder Cancer: Analysis of a Large Modern Cohort
Fistula formation is a rare and poorly described complication following radical cystectomy with urinary diversion. We sought to identify patients who experienced any type of fistulous complication and we analyzed risk factors for formation as well as management outcomes. We retrospectively reviewed the records of patients who underwent radical cystectomy for bladder cancer at our institution. Patients who experienced any fistula were identified. Risk factors, management strategies and outcomes were analyzed. Patients underwent initial conservative treatment and those in whom this treatment failed underwent surgical repair. Univariable and multivariable analyses were performed to identify predictors of fistula formation as well as the need for surgical repair. Of the 1,041 patients 31 (3.0%) experienced fistula formation. Median time to fistula presentation was 31 days. Enterodiversion was the most common fistula type, noted in 54.8% of patients, followed by enterocutaneous and diversion cutaneous treatment in 29.0% and 12.9%, respectively. On multivariable analyses a history of radiation therapy (OR 3.1, p = 0.03) and an orthotopic neobladder (OR 3.1, p = 0.04) were predictors of fistula formation. Conservative management was successful in 41.9% of cases. There were no predictors of failed conservative management. Of patients who required surgical repair success was achieved in 94.4% at a single operation. Fistulas are rare after radical cystectomy and they are most common between the urinary diversion and the small bowel. A history of radiation therapy and a orthotopic neobladder are risk factors for formation. When required, surgical repair is generally successful at a single operation.